[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abortion-habitual\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abortion-habitual":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100579237","phase-1-autologous-decidual-like-natural-killer-cells-therapy-for-infertility-or-adverse-pregnancy-history-100579237",false,"NCT06821685","Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History","Clinical Study of Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History Caused by Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* abnormal uterine NK cell function;\n* have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;\n* have clear fertility desires;\n* normal ovarian function or with frozen embryos;\n* edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \\>= 7mm;\n* 18kg\u002Fm\\^2 \\\u003C Body mass index \\\u003C 30kg\u002Fm\\^2;\n\nExclusion Criteria:\n\n* using progesterone receptor modulator;\n* chromosomal karyotype abnormalities in one spouse;\n* severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;\n* uncontrolled autoimmune diseases;\n* abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study;\n* history of pelvic malignant tumors;\n* currently participating in other clinical studies;\n* allergic to blood products.","FEMALE","22 Years","40 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.",[27,28,29,30],"Abortion, Habitual","Infertility Unexplained","Embryo Implantation","Pre-Eclampsia",[32,33,34,35],"recurrent pregnancy loss","repeated implantation failure","unexplained infertility","decidual natural killer cells","RECRUITING","2025-11-13",{"date":39,"type":40},"2025-11-17","ACTUAL",{"date":42,"type":40},"2025-02-13",{"date":44,"type":21},"2027-12",{"name":46,"class":47},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100592887","phase-3-light-trial-levothyroxine-for-gestational-hypothyroidism-in-recurrent-pregnancy-loss-100592887","NCT06999278","LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss","LIGHT - Levothyroxine for Isolated Gestational HypoThyroidism in Women With Recurrent Pregnancy Loss: a Multicenter Randomized, Double-blind, Placebo-controlled Trial - a Study Protocol","LIGHT","Inclusion Criteria:\n\n* women with singleton pregnancy\n* women with a history of recurrent pregnancy loss (defined as two or more pregnancy loss before 20wks)\n* women diagnosed with isolated maternal hypothyroidism (defined as isolated lower level of FT4 with normal TSH levels) in the current pregnancy before 20wks\n\nExclusion Criteria:\n\n* patients with known thyroid disorders\n* patients with antiphospholipid syndrome or other autoimmune conditions\n* patients with contraindications to levothyroxine (e.g., acute cardiac arrest, acute pancreatitis, acute myocarditis)\n* patients attending other ongoing clinical trials or unwilling to participate.","18 Years",{"count":59,"type":21},200,[61],"PHASE3","The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether levothyroxine supplement improves pregnancy outcomes in women with recurrent pregnancy loss (RPL) and isolated maternal hypothyroidism (IMH).\n\nThe main questions it aims to answer are:\n\nDoes levothyroxine increase the live birth rate after 24 weeks of gestation? Does levothyroxine improve secondary outcomes such as ongoing pregnancy rates, reduce the incidence of pregnancy loss, or influence maternal and neonatal complications?\n\nResearchers will:\n\nCompare the levothyroxine treatment group (50 µg\u002Fday) to the placebo group to assess the impact of the intervention on live birth rates and other pregnancy outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive either levothyroxine or a placebo. Take the assigned treatment daily starting from enrollment until the end of pregnancy.\n\nUndergo routine follow-up visits to monitor pregnancy progress and outcomes. This trial seeks to determine whether routine levothyroxine supplementation can improve pregnancy outcomes for women with RPL and IMH.",[27],[32,65,66,67,68,69],"isolated maternal hypothyroidism","levothyroxine","adverse pregnancy outcomes","live birth","neonatal complications","NOT_YET_RECRUITING","2025-05-31",{"date":73,"type":40},"2025-06-04",{"date":75,"type":21},"2025-06-01",{"date":77,"type":21},"2027-05-31",{"name":79,"class":47},"Women's Hospital School Of Medicine Zhejiang University"]